(P-2191) Efficacy and safety of buleviritide monotherapy for chronic hepatitis D in patients with and without cirrhosis: results from the week 144 interim analysis of a phase 3 randomized study

Saturday, October 19, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Co-Author(s)

SA

Soo Aleman, MD, PhD

Department of Infectious Diseases, Karolinska University Hospital/Karolinska Institutet, Stockholm, Sweden
Stockholm, Sodermanlands Lan, Sweden
HW

Heiner Wedemeyer, MD, PhD

Clinic for Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
Hannover, Niedersachsen, Germany
MB

Maurizia Brunetto, MD

Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, Pisa, Italy; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Pisa, Toscana, Italy
AB

Antje Blank, MD

Medical Faculty Heidelberg/Heidelberg University Hospital, Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany
Heidelberg, Baden-Wurttemberg, Germany
PA

Pietro Andreone, PhD

University of Modena and Reggio Emilia, Internal Medicine, Baggiovara Hospital
Modena, Emilia-Romagna, Italy
Pavel Bogomolov, MD, Ph.D (he/him/his)

Head of hepatology dept.
M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation
Moscow, Moskva, Russia
VC

Vladimir Chulanov, MD, PhD

Sechenov University
Moscow, Moskva, Russia
NM

Nina Mamonova, MD

FSBI National Research Medical Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
Moscow, Moskva, Russia
NG

Natalia Geyvandova, PhD

Stavropol Regional Hospital
Stavropol, Stavropol', Russia
VM

Viacheslav Morozov, MD, PhD

LLC Medical Company Hepatolog, Samara, Russian Federation
Samara, Samara, Russia
OS

Olga Sagalova, MD, PhD

South Ural State Medical University, Chelyabinsk, Russian Federation
Chelyabinsk, Moskva, Russia
TS

Tatyana Stepanova, MD

LLC Clinic of Modern Medicine, Moscow, Russian Federation
Moscow, Moskva, Russia

Co-Author(s)

GC

Grace Chee, PharmD

Gilead Sciences, Inc.
Foster City, California, United States

Presenting Author(s)

Dmitry Manuilov, MD

Sr. Director, Virology Clinical Development
Gilead Sciences, Inc.
Foster City, California, United States

Co-Author(s)

ML

Mingyang Li, PhD

Gilead Sciences, Inc.
Foster City, California, United States
AL

Audrey Lau, MD, PhD

Gilead Sciences, Inc.
Foster City, California, United States
AO

Anu Osinusi, MD

Clinical Research
Gilead
Foster City, California, United States
ST

Steve Tseng, MD

Gilead Sciences, Inc.
Foster City, California, United States
JS

Julian Schulze Zur Wiesch, MD, PhD

Hepatology Outpatient Medical Clinic, University Hospital Hamburg-Eppendorf, Hamburg, Germany
Hannover, Niedersachsen, Germany
MC

Markus Cornberg, MD, PhD

Clinic for Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
Hannover, Niedersachsen, Germany
SZ

Stefan Zeuzem, MD, PhD

Department of Medicine, University Hospital Frankfurt, Frankfurt am Main, Germany
Frankfurt, Hessen, Germany
PL

Pietro Lampertico, MD

CRC “A. M. and A. Migliavacca” Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan
Milan, Lombardia, Italy